U.S. CAR-T Cell Therapy Market Size, Share & Industry Analysis, By Drug (Yescarta, Tecartus, Carvykti, Abecma, Breyanzi, Kymriah, and Others), By Indication (Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma (NHL), and Multiple Myeloma), By End-user (Hospitals and Oncology Treatment Centers), and Country Forecast, 2024-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI109015

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2019-2032
Base Year	2023
Estimated Year	2024
Forecast Period	2024-2032
Historical Period	2019-2022
Growth Rate	CAGR of 18.7% from 2024 to 2032
Unit	Value (USD Billion)
Segmentation	By Drug Yescarta Tecartus Carvykti Abecma Breyanzi Kymriah Others
	By Indication Acute Lymphoblastic Leukemia (ALL) Non-Hodgkin Lymphoma (NHL) Multiple Myeloma
	By End-user Hospitals Oncology Treatment Centers